Country: Australia
Language: English
Source: Department of Health (Therapeutic Goods Administration)
lenacapavir sodium, Quantity: 306.8 mg (Equivalent: lenacapavir, Qty 300 mg)
Gilead Sciences Pty Ltd
Tablet, film coated
Excipient Ingredients: copovidone; poloxamer; mannitol; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350; iron oxide black
Oral
5 tablets
(S4) Prescription Only Medicine
SUNLENCA, in combination with other antiretrovirals, is indicated for the treatment of adults with multidrug resistant HIV-1 infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen.
Visual Identification: LEN tablets are beige, capsule-shaped, filmcoated tablet, debossed with GSI on one side and 62L on the other side; Container Type: Blister Pack; Container Material: PVC/Al; Container Life Time: 36 Months; Container Temperature: Store below 30 degrees Celsius; Container Closure: Child resistant closure
Registered
2023-03-27
SUNLENCA v 1.0 (March 2023) 1 SUNLENCA™ CONSUMER MEDICINE INFORMATION (CMI) SUMMARY The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. This medicine is new or being used differently. Please report side effects. See the full CMI for further details. 1. WHY AM I USING SUNLENCA? SUNLENCA contains the active ingredient lenacapavir. SUNLENCA is used to treat adults who have HIV-1 that are resistant to many other antiretroviral medicines. SUNLENCA is prescribed in combination with other antiretroviral medicines. It is used to treat HIV infection in adults with limited treatment options (for example when other antiretroviral medicines are not sufficiently effective or are not suitable). . For more information, see Section 1. Why am I using SUNLENCA? in the full CMI. 2. WHAT SHOULD I KNOW BEFORE I USE SUNLENCA? Do not use if you have ever had an allergic reaction to SUNLENCA or any of the ingredients listed at the end of the CMI. TALK TO YOUR DOCTOR IF YOU HAVE ANY OTHER MEDICAL CONDITIONS, TAKE ANY OTHER MEDICINES, OR ARE PREGNANT OR PLAN TO BECOME PREGNANT OR ARE BREASTFEEDING. For more information, see Section 2. What should I know before I use SUNLENCA? in the full CMI. 3. WHAT IF I AM TAKING OTHER MEDICINES? Some medicines may interfere with SUNLENCA and affect how it works. A list of these medicines is in Section 3. What if I am taking other medicines? in the full CMI. 4. HOW DO I USE SUNLENCA? • Your treatment with SUNLENCA starts with tablets taken on Days 1, 2, and 8 followed by two injections on Day 15, and then continues with two injections every six months. • Talk to your doctor before taking SUNLENCA tablets. More instructions can be found in Section 4. How do I use SUNLENCA? in the full CMI. 5. WHAT SHOULD I KNOW WHILE USING SUNLENCA? THINGS YOU SHOULD DO • Remind any doctor, dentist or pharmacist you visit that you are using SUNLENCA. • Attend your planned appointments every 6 months to receive your SUNLENCA injection. Read the complete document
SUNLENCA Product Information v 1.0 – 27 March 2023 Page 1 This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems . AUSTRALIAN PRODUCT INFORMATION SUNLENCA (LENACAPAVIR (AS SODIUM)) INJECTION, TABLETS 1 NAME OF THE MEDICINE Lenacapavir sodium 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each single-dose vial contains lenacapavir sodium equivalent to 463.5 mg/1.5 mL of lenacapavir. Each tablet contains lenacapavir sodium equivalent to 300 mg of lenacapavir. For the full list of excipients, see Section 6.1 List of excipients. 3 PHARMACEUTICAL FORM Solution for injection. Clear, yellow to brown solution with an apparent pH of 9.0 to 10.2 and a viscosity not more than 300 cP. Film-coated tablet (tablet). Beige, capsule-shaped, film-coated tablets, of dimensions 10 mm x 21 mm debossed with “GSI” on one side of the tablet and “62L” on the other side of the tablet. 4 CLINICAL PARTICULARS 4.1 T HERAPEUTIC INDICATIONS SUNLENCA, in combination with other antiretrovirals, is indicated for the treatment of adults with multidrug resistant HIV-1 infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen. 4.2 D OSE AND METHOD OF ADMINISTRATION SUNLENCA should be prescribed by physicians experienced in the treatment of HIV. Prior to starting SUNLENCA, the healthcare professional should carefully select patients who agree to the required injection schedule. To help maintain viral suppression and reduce the risk of viral rebound and potential development of resistance associated with missed doses, the healthcare professional should also counsel patients about the importance of adherence to both the scheduled dosing visits and the optimised background regimen. The recommended SUNLENCA treatment regimen in adults consists of an initiation dosing period (oral tablets and subcutaneous injections) and onc Read the complete document